Pallas Capital Advisors LLC Invests $1.13 Million in Medpace Holdings, Inc. $MEDP

Pallas Capital Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,142 shares of the company’s stock, valued at approximately $1,134,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Deutsche Bank AG purchased a new stake in Medpace in the second quarter worth approximately $2,477,000. Rice Hall James & Associates LLC purchased a new stake in Medpace during the 2nd quarter valued at $28,659,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Medpace during the 2nd quarter valued at $34,000. OneDigital Investment Advisors LLC purchased a new stake in Medpace during the 2nd quarter valued at $276,000. Finally, HBK Sorce Advisory LLC bought a new position in shares of Medpace during the 2nd quarter valued at $2,533,000. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares in the company, valued at $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 458 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $600.39, for a total value of $274,978.62. Following the completion of the transaction, the chief executive officer directly owned 603,978 shares in the company, valued at $362,622,351.42. This trade represents a 0.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 67,195 shares of company stock worth $37,989,998. Company insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research reports. Mizuho raised their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. BMO Capital Markets increased their target price on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Robert W. Baird raised their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and boosted their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $584.18.

Medpace Price Performance

Shares of Medpace stock opened at $590.30 on Wednesday. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company’s fifty day simple moving average is $541.49 and its 200-day simple moving average is $491.49. The stock has a market capitalization of $16.48 billion, a PE ratio of 34.60, a P/E/G ratio of 2.58 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the business posted $3.10 EPS. Medpace’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.